Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
Lexaria Bioscience Corp. (NASDAQ:LEXX) has terminated its Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, effective September 19, 2025. The agreement, originally entered into on August 21, 2024, and later amended on February 5, 2025, allowed Lexaria to issue and sell up to $5 million in aggregate principal amount of its common stock through JonesTrading as sales agent or principal.
According to a statement made in a press release, Lexaria sold a total of 14,995 shares under the agreement, generating gross proceeds of $38,236 by the time of termination. The company’s common stock and warrants are listed on the Nasdaq Capital Market under the symbols LEXX and LEXXW, respectively.
No further details regarding the reasons for the termination were provided in the filing. The information is based on a statement released in a U.S. Securities and Exchange Commission filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.